Participated · Series B · Jan 2023

Synergia Medical is a preclinical medical device company that has developed NAO.VNS, a non‑metal optoelectronic neurostimulator for vagus nerve stimulation to treat drug‑resistant epilepsy. The company is preparing for First‑In‑Human clinical trials planned for early 2024. It is ISO 13485 certified, operational since 2015, and based in Belgium with a staff of 27 focused on preclinical studies, R&D, quality, and regulatory affairs. Synergia holds a portfolio of nine patents in 15 families and is supported by Wallonia Region grants and the European Innovation Council (Accelerator financing). The team includes co‑founders Attila Borbath (CEO) and Pascal Doguet, and the company has both a business‑oriented Board of Directors and a Scientific Advisory Board of experts in neural stimulation and epilepsy. Financially, the company has previously raised funding and uses the recent proceeds to advance toward clinical milestones. Founded in 2013 by Pascal Doguet and Attila Borbath, Synergia Medical develops opto-electronics medical devices for neurostimulation. Its lead product, NAOS, is a small-form, MRI-safe, implanted neurostimulation device targeting drug-resistant epilepsy with additional therapeutic applications. The company is conducting advanced-stage testing of NAOS ahead of a CE mark filing expected in 2019. Synergia intends to use the funding to complete final testing prior to CE mark submission. The company is also preparing for regulatory approval efforts in the United States where neurostimulation use is increasing. The Series A financing strengthens its position to advance regulatory and commercialization milestones.

Participated · Series B · Nov 2022

Novadip Biosciences develops a 3M³ adipose-derived stem cell tissue regeneration platform intended to deliver one-time or off-the-shelf therapies for large bone defects and related orthopedic indications. Its lead allogeneic product, NVD-X3, is designed as an off-the-shelf matrix to accelerate durable bone union in spinal fusion and non-healing fractures and can be stored at room temperature for easy distribution. Its autologous program, NVD-003, targets critical-size bone defects such as congenital pseudarthrosis of the tibia (CPT) and is supported by Phase 1b/2a and compassionate-use data from more than 50 adult and pediatric patients with up to five years of follow-up. Novadip plans to initiate a Phase 1/2 trial for NVD-X3 in Europe and Phase 1b/2a CPT trials in the US and EU by end of 2022. NVD-003 has received orphan drug and rare pediatric disease designations from the FDA; if approved, the company could be eligible for a priority review voucher worth more than $100 million. The company estimates a $7 billion addressable market for its 3MALLO program and a $2.2 billion peak sales opportunity for NVD-X3; Novadip is headquartered in Mont Saint-Guibert, Belgium and was co-founded in 2013. Novadip Biosciences is a clinical-stage company leveraging its proprietary 3M³ 3D extracellular-matrix platform, which uses adipose-derived stem cells to deliver growth factors and miRNAs for tissue reconstruction. Its lead autologous product, NVD-003, has positive interim Phase I/IIa adult data and an FDA IND allowing a US pilot study in pediatric congenital pseudarthrosis of the tibia (ages 2–8). The company is also developing an allogeneic off-the-shelf product, NVD-X3, with a first clinical trial expected in 2022, and is exploring exosomal miRNA applications for solid tumors with trials planned in the US and Europe. Novadip was spun off from the University of Louvain (UCL) and Saint-Luc University Hospital and is advancing both autologous and allogeneic programs to address critical-size bone reconstruction and broader indications. The financing announced strengthens the balance sheet to support continued clinical development, platform innovation and potential future clinical paths in China. The company is based in Mont Saint-Guibert, Belgium. Novadip Biosciences is a biopharmaceutical spin‑off of Université catholique de Louvain advancing Creost, a ready‑to‑use natural three‑dimensional tissue that can be modelled to fill large and small bone defects. Creost will initially be investigated for complex lumbar spine fusion, an unmet medical need affecting more than 100,000 patients per year worldwide. The company plans to use the proceeds from its recent financing for clinical development and process industrialization of its lead compound. Leadership includes CEO and co‑founder Jean‑François Pollet and CSO and co‑founder Denis Dufrane. The technology originates from research led by Prof Denis Dufrane at the Cell and Tissue Therapy Centre of St Luc University Hospital and Université catholique de Louvain. Novadip closed a €28M Series A to fund these next development steps.

Participated · Equity · Oct 2022

Intressa Vascular (formerly Cardiatis SA) is a clinical-stage MedTech company based in Gembloux, Belgium. It has developed a proprietary braiding technology platform that produces multilayer stents. Its lead product, the Allay™ Aortic Stent, is designed to treat Type B aortic dissections (TBAD) and residual dissections by recentralizing blood flow inside the true lumen while preserving branch perfusion via a streamlined procedure. The company is led by CEO Pierre Douette and CSO Diane Lejeune. Intressa intends to use recent financing to support clinical development and product registration activities and to further anchor and develop the organization locally. The company recently completed an €18m financing package to advance these objectives.

Participated · Equity · Sep 2022

Founded in 2004, I-care Group develops hardware sensors and an AI-powered software platform that monitor industrial equipment to predict failures and optimize maintenance. Its subscription-based Wi-care as a Service offering combines in-house–manufactured vibration sensors (capacity up to 2,000 units per day) with the I-see platform, which already tracks data from more than 150,000 sensors worldwide. The company has grown into an international organization with 36 offices across 16 countries and serves customers in over 55 nations. I-care reports consolidated annual revenue exceeding €100 million, an order book above €200 million, and a workforce of more than 1,000 employees. Management is executing a three-phase growth plan that includes the current internal financing, a larger external investor round targeted for 2026, and an eventual IPO. Over the past eight years, I-care has completed eight acquisitions to expand its reach and capabilities. The firm’s heavy investment in R&D and early bet on AI underpin its competitive edge in the rapidly expanding predictive maintenance market.

Participated · Equity · Feb 2022

Aerospacelab designs, manufactures and operates satellites. The company closed a €94 million financing package comprising a €56 million Series B and a €38 million commitment from a European financial institution. The Series B was executed in two tranches to accelerate its industrial roadmap and consolidate its position in the aerospace ecosystem, the company said. Aerospacelab is building a “Megafactory” in Marcinelle (Wallonia) to scale production; the site is described as one of Europe’s most advanced satellite production facilities. The Megafactory is planned to begin satellite production in 2026 and to reach a maximum manufacturing capacity of up to 500 satellites per year by 2027. CEO and founder Benoît Deper said the funding will enable the company to design, manufacture and deploy next-generation constellations at very large scale. Aerospacelab builds end-to-end satellite systems and sensors, handling design, manufacturing, testing and in-orbit operations. The company emphasizes “true sensor fusion,” the simultaneous tasking of different satellite assets (radar and optical) to provide richer geospatial intelligence. In 2021 it launched its first satellite, a 12-unit cubesat called Arthur, on SpaceX’s Transporter-2 mission. The firm plans to ramp up satellite production capacity, deploy multiple constellations for intra-daily Earth monitoring, and implement geospatial data fusion analytics capabilities. Aerospacelab has secured strategic backing from investors and space-industry organizations as it scales its industrial and technological roadmap. Financially, the company has raised funding rounds since its 2018 founding, including the latest Series B.